- Advanced breast carcinoma. Is it an indication for bevacizumab use?2015 | First Faculty of Medicine
- Metastatic HER2-positive breast cancer - a new standard of treatment2015 | First Faculty of Medicine
- Overview of biological therapy for HER2-positive metastatic breast cancer2015 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Therapeutic options in patients with early breast cancer2023 | First Faculty of Medicine
- První a druhá linie léčby metastatického HER2 pozitivního karcinomu prsu2017 | First Faculty of Medicine
- Adjuvantní a neoadjuvantní léčba časného HER pozitivního karcinomu prsu. Specifika léčby HER2 pozitivního / HR pozitivního karcinomu prsu2022 | Publication without faculty affiliation
- Promising treatment options of triple negative breast cancer2017 | First Faculty of Medicine, Central Library of Charles University
- The treatment of metastatic HER2-positive breast cancer is extending2020 | First Faculty of Medicine
- Prognostic and predictive factors of breast cancer in clinical practice2012 | Faculty of Medicine in Pilsen
- Guillain-Barre Syndrome Associated with Breast Cancer Treated with Trastuzumab - a Case Report2013 | First Faculty of Medicine
- The importance of dual HER2 blockade in early HER2-positive breast cancer2023 | First Faculty of Medicine
- Effect of neoadjuvant Herceptin (trastuzumab) in a patient with breast cancer with high growth activity2009 | First Faculty of Medicine
- Targeted therapy in HER2-positive breast cancer2013 | Faculty of Medicine in Hradec Králové
- Clinical importance of her-3 in breast cancer2020 | First Faculty of Medicine, Third Faculty of Medicine
- Patients with neuregulin 1 (NRG1) rearranged cancer are suitable for the theranostic approach and targeted therapy2022 | Faculty of Medicine in Pilsen, Second Faculty of Medicine
- FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer2009 | Third Faculty of Medicine